PPIDT00308
Drug Information
| Name | Brodalumab |
|---|---|
| Sequence | Not Available |
| DrugBank_ID | DB11776 |
| Type | biotech |
| Indication | Brodalumab has been approved for the treatment of psoriasis vulgaris, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma. |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection, solution | Parenteral; Subcutaneous |
210 MG
|
| Injection, solution | Subcutaneous |
210 mg
|
| Injection | Parenteral |
210 MG
|
| Injection, solution | Subcutaneous |
210 mg/1.5mL
|
| Injection | Subcutaneous |
210 mg/1
|
| Solution | Subcutaneous |
210 mg / 1.5 mL
|